MORE: Novartis Says Oncology Head Herve Hoppenot to Leave

NOTE: Novartis Oncology is developing a promising new cancer therapy that faces challenges with how to administer and commercialize * NOTE: Earlier, Novartis Says Oncology Head Herve Hoppenot to Leave

Before it's here, it's on the Bloomberg Terminal.
LEARN MORE